Clinical Trial Update: A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp® [Phase 4]

View source ↗

Summary

Phase 4 study update evaluating symptom burden in patients with nonmyeloid malignancies receiving chemotherapy who are treated with Aranesp.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Anemia | Phase 4 | Status: COMPLETED